Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. The connection between diesel exhaust, allergies and climate change

The connection between diesel exhaust, allergies and climate change

Stories Sep 20, 2021 3 minutes

Researchers found that exposure to diesel exhaust particles exacerbated symptoms of hay fever—part of a rising trend associated with increasing pollution.

Particles from diesel exhaust worsened allergic reactions to ragweed, according to the results of a study led by Vancouver Coastal Health Research Institute (VCHRI) researcher Dr. Chris Carlsten. The first-of-its-kind study also demonstrated the effectiveness of the fexofenadine hydrochloride medication against symptoms of allergic rhinitis. 

“We know that particles from diesel fumes amplify the effects of allergens in many ways,” says Carlsten, co-director of the Centre for Lung Health. “This study highlights that the use of a medication provided some relief to patients, but more importantly emphasized the need to address the root of the problem and reduce exposure to irritants such as diesel exhaust.”  

Dr. Chris Carlsten is the director of the Occupational Lung Disease Clinic at The Lung Centre, as well as a professor and division head of Respiratory Medicine in the School of Population and Public Health and the endowed Chair in Occupational and Environmental Lung Disease at the University of British Columbia.

Another term for hay fever, allergic rhinitis is the reaction that occurs following exposure to an allergen, such as dust, certain foods, pollen or animal dander. It affects between 20 and 25 per cent of the Canadian population with symptoms such as a runny nose, itchy eyes, sneezing, eczema, fatigue and, in extreme cases, difficulty breathing.

Studies have shown an increased prevalence of allergic rhinitis over time, largely due to pollution and climate change. The plant growing season is lengthening in many areas due to a warming climate, which also extends the allergy season. More CO2 and hotter temperatures also contribute to worsened air quality, which is further compromised by pollution from industrial activities, vehicles, such as those with diesel engines, as well as other sources. 

Diesel exhaust particles’ small size—around 2.5 microns in diameter, which is a fraction of the approximate 70 microns in diameter of a human hair—makes them more capable of infiltrating airway cells. Once there, they irritate tissues, leading to inflammation and cell death, says Carlsten.  

“Allergens take a massive toll on quality of life, and can be a risk factor for mortality. Combined with pollution, the impacts can be quite significant.”

A potential path forward for allergy sufferers to breathe easier

Carlsten’s double-blind and randomised Phase 3 clinical investigation involved 251 adults ages 18-65 who had a prior two-year history of seasonal allergic rhinitis. The three-stage study tested exposure to ragweed—a common seasonal allergen responsible for hay fever symptoms—in combination with diesel exhaust particles and fexofenadine at different stages. 

The Health Canada and internationally approved fexofenadine antihistamine uses a selective histamine H1-receptor antagonist to block the histamine chemical found in some of the body’s cells. This prevents histamines from marking allergens as harmful invaders and eliciting an immune response that leads to hay fever symptoms.

Dr. Chris Carlsten is a 2020 recipient of a VCHRI COVID-19 Research Fund grant, which will go towards his investigation into the development of a COVID-19 respiratory registry database to support COVID-19 risk factor identification and inform clinical care.

Study participants were exposed to ragweed pollen for three hours during the first stage of the trial, and ragweed and diesel exhaust particles two weeks later for the second stage. 

The final stage involved exposing participants to ragweed and diesel exhaust particles for three hours and administering a 180 milligram tablet of fexofenadine or placebo at the two-hour mark to equal halves of the study cohort. Researchers collected participants’ self-assessments over the course of the trial.

The research team found that the three-hour exposure to ragweed and diesel exhaust particles increased participants’ seasonal allergic rhinitis symptoms by almost 14 per cent. Conversely, fexofenadine reduced self-reported scale of symptom severity from exposure to ragweed and diesel exhaust particles from a mean of around 60.4 percent to 30.9 per cent. The placebo severity score was a mean of 43.9 per cent.

“We hope that these results will give a bit of reassurance that, although these allergic conditions do seem to be getting worse over the years, there is at least a straightforward medication that can potentially help relieve some of these symptoms,” says Carlsten. 

“However, this is also a reality check that we do not want this trend to continue; because, throwing medications at the problem is not sufficient.”
 

Researchers

Christopher Carlsten

Related Articles

COVID-19 detection with point-of-care ultrasound technology

Research finds encouraging trends in B.C.’s approach to severe asthma

Preventing symptom escalation among mild COVID-19 patients

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Centre for Lung Health

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Investigator Awards 2023 Recipients

Mar 21, 2023 award
Type
Stories

Ask an expert: Is my menstrual pain normal, or could I have endometriosis?

Mar 16, 2023 women, endometriosis, preventative
Type
Stories

Honing in on precision treatments for endometriosis

Mar 14, 2023 genetics, treatment options
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy